BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26643855)

  • 21. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
    Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
    Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
    Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
    Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The epidemiology of gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Chan A; Svejda B; Kidd M; Modlin IM
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):1-18, vii. PubMed ID: 21349409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types.
    Oberg K; Astrup L; Eriksson B; Falkmer SE; Falkmer UG; Gustafsen J; Haglund C; Knigge U; Vatn MH; Välimäki M;
    Acta Oncol; 2004; 43(7):626-36. PubMed ID: 15545183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine receptor expression and function in corticotroph ectopic tumors.
    Pivonello R; Ferone D; de Herder WW; Faggiano A; Bodei L; de Krijger RR; Lombardi G; Colao A; Lamberts SW; Hofland LJ
    J Clin Endocrinol Metab; 2007 Jan; 92(1):65-9. PubMed ID: 17032724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resectability of primary gastroenteropancreatic neuroendocrine tumor as a prognostic factor for survival.
    Medrano-Guzmán R; López-García SC; Torres-Vargas S; González-Rodríguez D; Alvarado-Cabrero I
    Cir Cir; 2011; 79(6):498-504. PubMed ID: 22169366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
    Mosquera C; Koutlas NJ; Fitzgerald TL
    Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion.
    Tsagarakis S; Tsigos C; Vasiliou V; Tsiotra P; Kaskarelis J; Sotiropoulou C; Raptis SA; Thalassinos N
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1646-53. PubMed ID: 11932296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution.
    Guo LJ; Wang CH; Tang CW
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):284-8. PubMed ID: 27170574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
    Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
    JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time from first tumor manifestation to diagnosis in patients with GEP-NET: Results from a large German tertiary referral center.
    Koch C; Koca E; Filmann N; Husmann G; Bojunga J
    Medicine (Baltimore); 2021 Sep; 100(37):e27276. PubMed ID: 34664885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.
    Schimmack S; Svejda B; Lawrence B; Kidd M; Modlin IM
    Langenbecks Arch Surg; 2011 Mar; 396(3):273-98. PubMed ID: 21274559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TNF-alpha promoter single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine tumors.
    Berković M; Cacev T; Zjacić-Rotkvić V; Kapitanović S
    Neuroendocrinology; 2006; 84(5):346-52. PubMed ID: 17164537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
    Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
    Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.
    Faggiano A; Ferolla P; Grimaldi F; Campana D; Manzoni M; Davì MV; Bianchi A; Valcavi R; Papini E; Giuffrida D; Ferone D; Fanciulli G; Arnaldi G; Franchi GM; Francia G; Fasola G; Crinò L; Pontecorvi A; Tomassetti P; Colao A
    J Endocrinol Invest; 2012 Oct; 35(9):817-23. PubMed ID: 22080849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Lee MR; Harris C; Baeg KJ; Aronson A; Wisnivesky JP; Kim MK
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2212-2217.e1. PubMed ID: 30580091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas.
    Kamp K; Damhuis RA; Feelders RA; de Herder WW
    Endocr Relat Cancer; 2012 Feb; 19(1):95-9. PubMed ID: 22194442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland.
    Alwan H; La Rosa S; Andreas Kopp P; Germann S; Maspoli-Conconi M; Sempoux C; Bulliard JL
    Cancer Med; 2020 Dec; 9(24):9454-9461. PubMed ID: 33078908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms.
    Daskalakis K; Chatzelis E; Tsoli M; Papadopoulou-Marketou N; Dimitriadis GK; Tsolakis AV; Kaltsas G
    Endocrine; 2019 May; 64(2):384-392. PubMed ID: 30280284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease?
    Fitzgerald TL; Dennis SO; Kachare SD; Vohra NA; Zervos EE
    Surgery; 2015 Aug; 158(2):466-71. PubMed ID: 26013986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.